TrialLeukemia & lymphoma2025

Results from an open-label phase 2a study of cerdulatinib, a dual spleen tyrosine kinase/janus kinase inhibitor, in relapsed/refractory peripheral T-cell lymphoma.

Steven M Horwitz et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.